APA citiranje

van der Horst, H. J., Gelderloos, A. T., Chamuleau, M. E. D., Breij, E. C. W., Zweegman, S., Nijhof, I. S., . . . Mutis, T. (2021). Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv.

Citação norma Chicago

van der Horst, Hilma J., Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, and Tuna Mutis. "Potent Preclinical Activity of HexaBody-DR5/DR5 in Relapsed And/or Refractory Multiple Myeloma." Blood Adv 2021.

MLA citiranje

van der Horst, Hilma J., et al. "Potent Preclinical Activity of HexaBody-DR5/DR5 in Relapsed And/or Refractory Multiple Myeloma." Blood Adv 2021.